Yantai Zhenghai Bio-Tech Co Ltd (300653) - Net Assets
Based on the latest financial reports, Yantai Zhenghai Bio-Tech Co Ltd (300653) has net assets worth CN¥904.23 Million CNY (≈ $132.32 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.00 Billion ≈ $146.75 Million USD) and total liabilities (CN¥98.66 Million ≈ $14.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300653 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥904.23 Million |
| % of Total Assets | 90.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | 13.27% |
| 10-Year Change | 289.85% |
| Growth Volatility | 57.66 |
Yantai Zhenghai Bio-Tech Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Yantai Zhenghai Bio-Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Yantai Zhenghai Bio-Tech Co Ltd market capitalisation.
Annual Net Assets for Yantai Zhenghai Bio-Tech Co Ltd (2012–2025)
The table below shows the annual net assets of Yantai Zhenghai Bio-Tech Co Ltd from 2012 to 2025. Also explore Yantai Zhenghai Bio-Tech Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥889.48 Million ≈ $130.16 Million |
+0.08% |
| 2024-12-31 | CN¥888.78 Million ≈ $130.06 Million |
-6.25% |
| 2023-12-31 | CN¥948.07 Million ≈ $138.73 Million |
+9.59% |
| 2022-12-31 | CN¥865.11 Million ≈ $126.59 Million |
+10.17% |
| 2021-12-31 | CN¥785.27 Million ≈ $114.91 Million |
+21.42% |
| 2020-12-31 | CN¥646.72 Million ≈ $94.64 Million |
+9.91% |
| 2019-12-31 | CN¥588.38 Million ≈ $86.10 Million |
+11.23% |
| 2018-12-31 | CN¥529.00 Million ≈ $77.41 Million |
+9.48% |
| 2017-12-31 | CN¥483.18 Million ≈ $70.70 Million |
+111.77% |
| 2016-12-31 | CN¥228.16 Million ≈ $33.39 Million |
+27.18% |
| 2015-12-31 | CN¥179.40 Million ≈ $26.25 Million |
+181.98% |
| 2014-12-31 | CN¥63.62 Million ≈ $9.31 Million |
+116.87% |
| 2013-12-31 | CN¥29.34 Million ≈ $4.29 Million |
+556.19% |
| 2012-12-31 | CN¥-6.43 Million ≈ $-941.02K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yantai Zhenghai Bio-Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 51715797370.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥490.78 Million | 55.18% |
| Other Components | CN¥398.70 Million | 44.82% |
| Total Equity | CN¥889.48 Million | 100.00% |
Yantai Zhenghai Bio-Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Yantai Zhenghai Bio-Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BTQ Technologies Corp.
NEO:BTQ
|
$398.98 Million |
|
Wuhu Fuchun Dye and Weave Co.Ltd.
SHG:605189
|
$399.02 Million |
|
Goldiam International Limited
NSE:GOLDIAM
|
$399.02 Million |
|
ProKidney Corp.
NASDAQ:PROK
|
$399.05 Million |
|
Jiangsu Junxia Gym Equipment Co. Ltd. A
SHE:301287
|
$398.72 Million |
|
Hangzhou Everfine Photo E Info
SHE:300306
|
$398.69 Million |
|
Foresee Pharmaceuticals Co Ltd
TWO:6576
|
$398.59 Million |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
$398.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yantai Zhenghai Bio-Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 888,784,131 to 889,479,886, a change of 695,755 (0.1%).
- Net income of 82,410,132 contributed positively to equity growth.
- Dividend payments of 81,714,377 reduced retained earnings.
- Other comprehensive income decreased equity by 99,202,234.
- Other factors increased equity by 99,202,235.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥82.41 Million | +9.26% |
| Dividends Paid | CN¥81.71 Million | -9.19% |
| Other Comprehensive Income | CN¥-99.20 Million | -11.15% |
| Other Changes | CN¥99.20 Million | +11.15% |
| Total Change | CN¥- | 0.08% |
Book Value vs Market Value Analysis
This analysis compares Yantai Zhenghai Bio-Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥-0.12 | CN¥15.14 | x |
| 2013-12-31 | CN¥0.55 | CN¥15.14 | x |
| 2014-12-31 | CN¥1.20 | CN¥15.14 | x |
| 2015-12-31 | CN¥1.46 | CN¥15.14 | x |
| 2016-12-31 | CN¥1.70 | CN¥15.14 | x |
| 2017-12-31 | CN¥2.99 | CN¥15.14 | x |
| 2018-12-31 | CN¥2.93 | CN¥15.14 | x |
| 2019-12-31 | CN¥3.25 | CN¥15.14 | x |
| 2020-12-31 | CN¥3.61 | CN¥15.14 | x |
| 2021-12-31 | CN¥4.38 | CN¥15.14 | x |
| 2022-12-31 | CN¥5.97 | CN¥15.14 | x |
| 2023-12-31 | CN¥5.26 | CN¥15.14 | x |
| 2024-12-31 | CN¥4.95 | CN¥15.14 | x |
| 2025-12-31 | CN¥4.94 | CN¥15.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yantai Zhenghai Bio-Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.26%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.63%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.11x
- Recent ROE (9.26%) is below the historical average (21.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 14.36% | 0.65x | 0.00x | CN¥9.16 Million |
| 2013 | 53.75% | 20.38% | 0.99x | 2.65x | CN¥12.83 Million |
| 2014 | 52.91% | 31.96% | 1.28x | 1.29x | CN¥27.30 Million |
| 2015 | 23.69% | 33.16% | 0.64x | 1.12x | CN¥24.55 Million |
| 2016 | 19.93% | 30.19% | 0.58x | 1.14x | CN¥22.65 Million |
| 2017 | 12.76% | 33.74% | 0.34x | 1.10x | CN¥13.35 Million |
| 2018 | 16.22% | 39.81% | 0.37x | 1.10x | CN¥32.92 Million |
| 2019 | 18.25% | 38.38% | 0.39x | 1.22x | CN¥48.55 Million |
| 2020 | 18.30% | 40.35% | 0.36x | 1.25x | CN¥53.66 Million |
| 2021 | 21.46% | 42.12% | 0.43x | 1.18x | CN¥90.03 Million |
| 2022 | 21.44% | 42.80% | 0.44x | 1.14x | CN¥98.93 Million |
| 2023 | 20.14% | 46.16% | 0.39x | 1.11x | CN¥96.15 Million |
| 2024 | 15.15% | 37.07% | 0.37x | 1.10x | CN¥45.76 Million |
| 2025 | 9.26% | 22.63% | 0.37x | 1.11x | CN¥-6.54 Million |
Industry Comparison
This section compares Yantai Zhenghai Bio-Tech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,630,540,352
- Average return on equity (ROE) among peers: 6.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yantai Zhenghai Bio-Tech Co Ltd (300653) | CN¥904.23 Million | 0.00% | 0.11x | $398.78 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $89.81 Million | 2.75% | 1.57x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $445.86 Million | 0.46% | 0.45x | $483.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $712.38 Million | 3.28% | 0.06x | $575.51 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.67 Billion | 2.43% | 1.21x | $1.61 Billion |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $3.46 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $25.90 Billion | 5.00% | 0.05x | $4.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.44 Billion | 2.86% | 0.17x | $428.14 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.62 Billion |
About Yantai Zhenghai Bio-Tech Co Ltd
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral restoration membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etching agent, dental pit and fissure sealant, active biol… Read more